375
Participants
Start Date
August 29, 2024
Primary Completion Date
December 1, 2025
Study Completion Date
April 1, 2026
LMN-201
"LMN-201 consists of orally delivered whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from 4 separate strains, each of which has been engineered to express one of the following therapeutic proteins:~* 3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile~* 1 lysozyme-like enzyme that selectively degrades the cell wall of C. difficile and causes rapid destruction of the organism"
Placebo
Doses of placebo will be delivered as identical-appearing cornstarch with coloring in size 00, white, opaque, capsules.
RECRUITING
Weill Cornell Medicine, New York
RECRUITING
Clinical Alliance for Infectious Diseases - Infectious Diseases, LLC, Annandale
RECRUITING
IMA Clinical Research, Mount Airy
RECRUITING
Metro Infectious Disease Consultants - Atlanta, Decatur
RECRUITING
GI PROS Research, Naples
RECRUITING
Baptist Health Research, Lexington
RECRUITING
The Clinical Trials Network, LLC, Willoughby
RECRUITING
University of Minnesota, Minneapolis
RECRUITING
Mercury Street Medical, Butte
RECRUITING
DM Clinical Research, Oak Lawn
RECRUITING
Metro Infectious Disease Consultants, LLC, Burr Ridge
RECRUITING
Quality Clinical Research, Inc, Omaha
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
Snake River Research, Idaho Falls
RECRUITING
Kaiser Permanente, Escondido
RECRUITING
Bridgeport Hospital, Bridgeport
RECRUITING
Gastroenterology Center of Connecticut, Hamden
Lead Sponsor
Congressionally Directed Medical Research Programs
FED
Lumen Bioscience, Inc.
INDUSTRY